Key clinical trials of sparsentan sponsored by Travere Therapeutics

Drug(s)	Indication	Phase	Status	Location(s)	Identifier
Sparsentan, irbesartan, dapagliflozin	IgA nephropathy	III	ANR	Multinational	NCT03762850; EudraCT 2017-004605-41; PROTECT
Sparsentan, irbesartan	FSGS	III	ANR	Multinational	NCT03493685; EudraCT 2016-005141-23; DUPLEX
Sparsentan, Irbesartan	FSGS	II	ANR	Multinational	NCT01613118; EudraCT 2014-002358-38; DUET
Sparsentan	Proteinuric glomerular diseasesa	II	Recruiting	Multinational	NCT05003986; EudraCT 2021-000621-27; EPPIK

ANR active, not recruiting, FSGS focal segmental glomerulosclerosis, IgA immunoglobulin A

^aFSGS, minimal change disease, IgA nephropathy, IgA vasculitis or Alport syndrome in paediatric patients